Janux Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Janux Therapeutics, Inc. (JANX) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $28.58 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $28.58M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $52.64M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $53.15M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $49.20M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $28.58M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $52.64M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $53.15M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $49.20M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $53.26M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $74.56M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $431.42M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $27.57M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $15.48M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $213.62M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $20.02M 10-K · filed 2026-02-26 |
| 2023-09-30 | $17.97M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $34.52M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $31.17M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $52.24M 10-K · filed 2026-02-26 |
| 2022-09-30 | $65.57M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $59.22M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $55.95M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $36.40M 10-K · filed 2025-02-27 |
| 2021-09-30 | $39.39M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $251.63M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $70.77M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $7.81M 10-K · filed 2023-03-10 |
| 2020-09-30 | $4.89M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $6.00M 10-Q · filed 2021-08-10 |
| 2019-12-31 | $658.00K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |